Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
Elham GhanbarianDepartment of Neurology, University of California, Irvine, CA, USA.ORCID 0009-0009-1733-9928
Babak KhorsandDepartment of Neurology, University of California, Irvine, CA, USA.ORCID 0000-0002-1585-3909
Kellen K PetersenDepartment of Neurology, Washington University in St Louis, St Louis, MO, USA.ORCID 0000-0003-3195-3456
Bhargav T NallapuSaul B. Korey Department of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
S Ahmad SajjadiDepartment of Neurology, University of California, Irvine, CA, USA.
Richard B LiptonSaul B. Korey Department of Neurology, Albert Einstein College of Medicine, New York City, NY, USA.
Ali EzzatiDepartment of Neurology, University of California, Irvine, CA, USA.
Alzheimer's Disease Neuroimaging Initiative *
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI CAROL A. DERBY · 1985 to 2026
$73.9M
Neuroimaging CoreU19AG076581 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GABRIEL Alejandro DE ERAUSQUIN, Gabriela Gonzalez_Aleman · 2023 to 2026
$32.9M
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's diseaseR01AG075758 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Charles DeCarli, Hector M Gonzalez · 2022 to 2026
$21.7M
Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME)RM1DA055437 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ARNSTEN, JULIA H., BAO, YUHUA · 2021 to 2025
$13.7M
Diagnosis and Risk factors of hippocampal sclerosis of aging and limbic predominant age related TDP-43 encephalopathy; common Alzheimer’s mimicsR01AG062706 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Seyed Ahmad Sajjadi · 2019 to 2026
$9.2M
Validation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse PopulationsR01AG080635 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Ali Ezzati, Richard B. LIPTON · 2023 to 2026
$8.6M
Heading and Soccer: Understanding Cognitive Risks, Benefits, and the Potential Mediating Role of White MatterR01NS123374 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Michael Lawrence Lipton · 2022 to 2026
$3.6M
Feasibility and Acceptability of Telephone-delivered MBCT for Migraine and Depression (FATE-MD)R01AT011005 · NCCIH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SENG-TAMACCIO, ELIZABETH K, SHALLCROSS, AMANDA J · 2021 to 2024
$3.1M
COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settingsRF1AG057531 · NIA · UNIVERSITY OF NEW SOUTH WALES · PI SACHDEV, PERMINDER S · 2017 to 2020
$2.9M
Sensory Amplifications as Biomarkers of Migraine ProgressionR61NS125153 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BRENNAN, KEVIN CHRISTOPHER · 2023 to 2025
$2.2M
Early and life course socioeconomic adversity and dementia risk in Hispanics/LatinosRF1AG077639 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DECARLI, CHARLES, GONZALEZ, HECTOR M · 2022 to 2023
BackgroundNeuroinflammation actively contributes to the pathophysiology of Alzheimer's disease (AD); however, the value of neuroinflammatory biomarkers for disease-staging or predicting disease progression remains unclear.ObjectiveTo investigate diagnostic and prognostic utility of inflammatory biomarkers in combination with conventional AD biomarkers.MethodsData from 258 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) with cerebrospinal fluid (CSF) biomarkers of amyloid-β (Aβ), tau, and inflammation were analyzed. Clinically meaningful cognitive decline (CMCD) was defined as a ≥ 4-point increase on the Alzheimer's Disease Assessment Scale Cognitive Subscore 11. Predictor variables included demographics (D: age, sex, education),
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cerebrospinal fluid inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer's disease spectrum. · full record | OpenQuestion